Novartis announces commencement of tender offer to acquire Regulus Therapeutics

Novartis announces commencement of tender offer to acquire Regulus Therapeutics
arcticnovartis

Basel, May 27, 2025 – Novartis today announced that Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Regulus Therapeutics Inc., a Delaware corporation (“Regulus”), in exchange for (i) $7.00 in cash per Share, subject to any applicable withholding and without interest thereon, plus (ii) one contingent value right (each, a “CVR”) per Share, representing the right to receive one co

/by

Why advocating for your MS is so important

Why advocating for your MS is so important
hajdola1

/by

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
arcticnovartis

  • NATALEE subanalysis evaluates Kisqali in pre-menopausal early breast cancer patients, amid rising diagnosis rates in younger patients
  • Pluvicto analysis and Scemblix ASC4START primary endpoint results provide insights into use in earlier settings
  • Fabhalta APPULSE-PNH full results build on Phase III program, reporting new data from expanded PNH population in adults switching from anti-C5
/by

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
arcticnovartis

  • NATALEE subanalysis evaluates Kisqali in pre-menopausal early breast cancer patients, amid rising diagnosis rates in younger patients
  • Pluvicto analysis and Scemblix ASC4START primary endpoint results provide insights into use in earlier settings
  • Fabhalta APPULSE-PNH full results build on Phase III program, reporting new data from expanded PNH population in adults switching from anti-C5
/by

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
arcticnovartis

  • NATALEE subanalysis evaluates Kisqali in pre-menopausal early breast cancer patients, amid rising diagnosis rates in younger patients
  • Pluvicto analysis and Scemblix ASC4START primary endpoint results provide insights into use in earlier settings
  • Fabhalta APPULSE-PNH full results build on Phase III program, reporting new data from expanded PNH population in adults switching from anti-C5
/by

Vas Narasimhan named to 2025 TIME100 Health list

Vas Narasimhan named to 2025 TIME100 Health list
angilma1

/by

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
arcticnovartis

  • There is currently no evidence-based treatment for the smallest babies with malaria
  • The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic differences in babies under 5 kg
  • The CALINA trial indicated that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review

Basel, April 24, 2024 – Novartis and Medicines for Malaria Venture (MMV) announce positive data from the

/by

Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline

Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline
arcticnovartis

  • Transaction reinforces company’s strategic focus on developing next-generation treatment options for patients living with cancer
  • Mariana Oncology is a preclinical-stage biotechnology company focused on developing novel radioligand therapies (RLTs) to treat cancers with high unmet need
  • Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications

Basel, May 2, 2024 – Novartis today announced that it has entered into an agreement to acquire Mariana Oncology, a preclinical-stage bio

/by

Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA

Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA
arcticnovartis

  • Primary results of the Scemblix® ASC4FIRST pivotal Phase III study in first-line Ph+ CML-CP supporting third US FDA Breakthrough Therapy designation, to be detailed in the ASCO Press Program and the EHA Plenary Session
  • Latest data from the Kisqali®* NATALEE trial, including efficacy endpoints for patients with node-negative stage II and III HR+/HER2- early breast cancer
/by

Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash

Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
arcticnovartis

  • Novartis secured 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period, reaching the minimum 65% acceptance threshold
  • Settlement of the shares tendered during the initial acceptance period is expected to occur on 23 May 2024
  • Additional statutory acceptance period is expected to end on 30 May 2024 at 24:00 hours CEST
  • Transaction strengthens the Novartis pipeline in oncology, adding pelabresib, a late-stage BET inhibitor for myelofibrosis and tulmimetostat, an early-stage invest
/by